Overview

A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To examine the continued safety and tolerability of four doses of vesnarinone in HIV-infected patients who have completed a short-term study (less than 12 months on continuous treatment) of the drug.
Phase:
N/A
Details
Lead Sponsor:
Otsuka America Pharmaceutical
Treatments:
Vesnarinone